TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03388294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents and Infants Engaged
Description: A novel in-home parent coaching intervention addressing transactions between pre-linguistic communication and sensory reactivity in infants at-risk for autism and other NDs on the one hand, and parent responses to infant cues on the other hand, using live coaching and video feedback methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents and Infants Engaged
Description: A novel in-home parent coaching intervention addressing transactions between pre-linguistic communication and sensory reactivity in infants at-risk for autism and other NDs on the one hand, and parent responses to infant cues on the other hand, using live coaching and video feedback methods.
Study: NCT03434847

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants who receive perioperative educational to address their expectation about their postoperative pain will have improved pain-related postoperative outcomes.
Study: NCT01764009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: naked DNA coding for protein AMEP
Description: injections 28days interval of 3 increasing doses of plasmid with electrotransfer
Study: NCT00827983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 25 mg, s.c., once à day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 90 mg, vaginally, once à day
Study: NCT01216943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution
Description: One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
Study: NCT02467920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glargine + exenatide
Description: glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)
Study: NCT02297269

Intervention type: DEVICE
Intervention: laparoscopic surgery
Description: the method of surgery is conducted by laparoscope with proper pressure of pneumoperitoneum instead of opening the abdomen.

Intervention type: DEVICE
Intervention: open surgery
Description: the method of surgery is conducted by surgical instruments to open the abdomen.
Study: NCT01002950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACU-4429
Description: ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo tablets taken orally once daily for 90 days
Study: NCT03301038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.
Study: NCT03925740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MI Varnish
Description: Application of MI varnish material versus the standard 1.23% APF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PreviDent Varnish
Description: Application of PreviDent Varnish material versus the standard 1.23% APF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.23% APF
Description: Standard 1.23% APF application
Study: NCT04718142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vNEP
Description: Apply vNEP therapy to the anterior surface of the throat with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O and vNEP devices of varying shapes and sizes.
Study: NCT02441608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KL029 Intimate Lubricant Gel
Description: All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
Study: NCT04830787

Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention, we just chose patients diagnosed with hypertrophic cardiomyopathy and underwent CAG, and patients without hypertrophic cardiomyopathy as control ,the two groups are matched with age, gender and hypertension.
Study: NCT01239706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTx 265
Description: 10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin
Study: NCT04251221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Alcohol Challenge
Description: Subjects will drink an alcohol dose designed to achieve a BAL of 0.08

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Alcohol Challenge
Description: Subjects will drink an alcohol dose designed to achieve a BAL of 0.08
Study: NCT00762242

Intervention type: PROCEDURE
Intervention: blood sampling and brachial artery ultrasound
Description: Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes)~Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery.~Following completion of blood sampling, an additional resting image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation.
Study: NCT01685996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide
Description: In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03332576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: SubQ injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: SubQ injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: SubQ injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: SubQ injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: SubQ injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac(Aqueous)
Description: SubQ injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: PO BID
Study: NCT02467920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspart 30
Description: aspart 30 ( subcutaneous injection, twice daily)
Study: NCT01565941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: IV insulin titration to target a blood glucose of 80-110 mg/dL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: IV insulin titration to target a blood glucose of 150-180 mg/dL
Study: NCT02541136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Each exercise class consisted of a warm-up, an aerobic and a cool-down phase, supervised by a physiotherapist. The warm up and cool down phases consisted of 5-7 minutes of low intensity aerobic exercise, \< 40% Heart Rate Reserve (HHR), to allow the cardiopulmonary and musculoskeletal systems to adapt and recover, respectively.~The aerobic component initially consisted of 21 minutes at an intensity of 40-59% HRR and was progressed to 42 minutes at 55-75% HRR by week 8 until programme completion. All participants worked at the same intensity and duration at the various time points throughout the study. Continuous, rhythmic exercise using large muscle groups was prescribed using treadmills, cycle ergometers and other aerobic exercise that increased heart rate to its prescribed level.
Study: NCT03797092

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic adipose-derived stromal cells (CSCC_ASC)
Description: Active group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: No treatment
Study: NCT03123614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol Etabonate 0.5% Oph Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1% Oph Susp
Study: NCT04591743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TCS
Description: TCS active at 1 Hz on the right DLPFC for 6 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TCS
Description: Inactive TCS (placebo coil) at 1 Hz on right DLPFC for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine treatment
Description: at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine treatment
Description: at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: EVA on craving, TCQ, QSU, BDI-II, CO tester, IGT, BART

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: EVA on craving, TCQ, QSU, BDI-II, CO tester, IGT, BART
Study: NCT00973102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin IV
Description: One time dose of Premarin IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One time dose of placebo.
Study: NCT00376701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (Bevacizumab)
Description: Avastin 1.25 mg intravitreal
Study: NCT03332576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: PO BID
Study: NCT00376701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (Bevacizumab)
Description: Avastin 1.25 mg intravitreal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (Bevacizumab)
Description: Avastin 1.25 mg intravitreal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravitreal 1.25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravitreal 1.25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
Study: NCT03757130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 598
Description: AMG 598 administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 598
Description: AMG 598 administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 598
Description: AMG 598 administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 598
Description: AMG 598 administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 598
Description: AMG 598 administered by subcutaneous injection
Study: NCT02221284

Intervention type: DRUG
Intervention: Alogliptin
Description: Alogliptin tablets
Study: NCT02450110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Study: NCT02725242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (160/4.5 μg/d)
Description: After the patients who have all criteria, they will be randomization to take Budesonide/formoterol (160/4.5 μg/d)
Study: NCT03757130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 598
Description: AMG 598 administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to AMG 598 administered by subcutaneous injection
Study: NCT01878786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
Study: NCT03757130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching to AMG 598 administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.
Study: NCT00475865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for teriflunomide)
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glatiramer Acetate (GA)
Description: Solution in prefilled syringe for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (GA)
Description: Solution in prefilled syringe for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (GA)
Description: Solution in prefilled syringe for subcutaneous injection
Study: NCT02320851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SVD-tailored Integrative Psychotherapy (IPT)
Description: (see description of corresponding study arm)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help group (SHG)
Description: (see description of corresponding study arm)
Study: NCT01521910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low protein diet
Description: An iso-caloric low protein diet of 0.6 g/kg/day was prescribed during the whole study duration.~The same dietician gave nutritional advices at least every three months during the whole study period. Patients were also seen by the same doctor during each visit for the whole study period.~Supplementation of Calcium of 500mg/day.~Urine albumin losses \>= 2 g/day wre replaced by increasing dietary protein on a gram-for-gram basis, only if the patient was compliant with the prescribed low-protein diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: normal protein diet
Description: The patients pre-study diet during the whole study period~Patients were also seen by the same doctor during each visit for the whole study period.
Study: NCT03931915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 40 mg tablets + Leuprorelin acetate placebo injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin acetate
Description: TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection
Study: NCT03043677

Intervention type: BIOLOGICAL
Intervention: Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab
Description: Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.~Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems.

Intervention type: BIOLOGICAL
Intervention: Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab
Description: Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.~Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems.

Intervention type: BIOLOGICAL
Intervention: Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab
Description: Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.~Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems.
Study: NCT01900977

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Universal Testing with immediate ART
Description: • Combination prevention package including:~o House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Universal Testing with ART eligibility according to National Guidelines
Description: Combination prevention package including:~House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Study: NCT01903889

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinic based intervention
Description: counseling C\&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinic and community based intervention
Description: basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services
Study: NCT03099148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Formulation (R)
Description: Administered PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641 (T1)
Description: 20 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641 (T1)
Description: 20 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3337641 (T2)
Description: 20 mg PO
Study: NCT03455439

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: As prescribed by the treating physician
Study: NCT02338934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Cinacalcet with Vitamin D analogue
Description: Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal \<2.4 mmol/L - Start Cinacalcet 25mg OD \& Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if \>2.54 mmol/L - Start Cinacalcet 25mg OD \& Maintain active Vit D dose. Then they will go to maintenance phase.
Study: NCT01576328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: Single intravenous infusion of MPCs Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: Single intravenous infusion of MPCs Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: Single intravenous infusion of MPCs Dose 3